Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) shares gapped up before the market opened on Tuesday after Needham & Company LLC raised their price target on the stock from $30.00 to $38.00. The stock had previously closed at $14.19, but opened at $16.10. Needham & Company LLC currently has a buy rating on the stock. Viridian Therapeutics shares last traded at $15.98, with a volume of 6,540,406 shares.
A number of other brokerages have also recently weighed in on VRDN. Royal Bank of Canada restated an “outperform” rating and issued a $35.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, August 28th. HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of Viridian Therapeutics in a research report on Tuesday. BTIG Research raised their price target on Viridian Therapeutics from $46.00 to $56.00 and gave the company a “buy” rating in a research report on Tuesday. The Goldman Sachs Group assumed coverage on Viridian Therapeutics in a research report on Thursday, June 6th. They set a “buy” rating and a $23.00 price objective for the company. Finally, Oppenheimer restated an “outperform” rating and set a $28.00 target price (down previously from $31.00) on shares of Viridian Therapeutics in a research note on Monday, August 12th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $34.18.
Read Our Latest Stock Analysis on VRDN
Institutional Trading of Viridian Therapeutics
Viridian Therapeutics Price Performance
The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -4.40 and a beta of 1.03. The company has a quick ratio of 15.82, a current ratio of 15.82 and a debt-to-equity ratio of 0.05. The company’s 50-day moving average is $15.03 and its 200-day moving average is $14.99.
Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.15). The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.09 million. Viridian Therapeutics had a negative net margin of 79,185.77% and a negative return on equity of 83.18%. Equities research analysts expect that Viridian Therapeutics, Inc. will post -3.97 earnings per share for the current fiscal year.
Viridian Therapeutics Company Profile
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Featured Stories
- Five stocks we like better than Viridian Therapeutics
- Stock Market Sectors: What Are They and How Many Are There?
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- Investing in Commodities: What Are They? How to Invest in Them
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- CD Calculator: Certificate of Deposit Calculator
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.